CD276 and neuroblastoma: Drug-conjugated anti-B7-H3 mAbs [25] and chimeric antigen receptor (CAR)-transduced T cells [26] targeting B7-H3 have been explored in preclinical studies with very promising results and different clinical trials are ongoing in NB patients [27].